肿瘤坏死因子受体2：新的调节性T细胞开关？
TNFR2: The new Treg switch?
作者信息
Cohen José L, Wood Kathryn J
机构信息
Université Paris-Est, Unité mixte de recherche S955, Université Paris Est Créteil, Créteil, France; INSERM, U955, Equipe 21, Créteil, France; Assistance Publique Hôpitaux de Paris (APHP), Hôpital H. Mondor-A. Chenevier, Centre d'Investigation Clinique Biothérapie, Créteil, France.
Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
出版信息
Oncoimmunology. 2017 Sep 21;7(1):e1373236. doi: 10.1080/2162402X.2017.1373236. eCollection 2017.
Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TNF/TNR2 pathway as a swith and as a new target for immune checkpoint therapy to modulate the immune regulation in this clinical setting.
最近的三篇出版物将肿瘤坏死因子/肿瘤坏死因子受体2（TNF/TNR2）通路确定为一个新靶点，该靶点可通过调节性T细胞激活来减轻移植物抗宿主病，或在异基因造血干细胞移植中通过阻断调节性T细胞来潜在地开启强大的抗白血病效应。这将TNF/TNR2通路确定为一种开关以及免疫检查点疗法的一个新靶点，用于在这种临床环境中调节免疫调节。
Zotero 插件